

Geography in multiple sclerosis

Journal of Neurology

215, 1-26

DOI: [10.1007/bf00312546](https://doi.org/10.1007/bf00312546)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Histocompatibility antigens (HLA) in multiple sclerosis in Iran.. Journal of Neurology, Neurosurgery and Psychiatry, 1978, 41, 699-701.	1.9	9
2	Comparative epidemiology of multiple sclerosis and dental caries.. Journal of Epidemiology and Community Health, 1978, 32, 155-165.	3.7	42
3	Multiple sclerosis in the faroe islands: I. Clinical and epidemiological features. Annals of Neurology, 1979, 5, 6-21.	5.3	262
4	Multiple Sclerosis: A Critical Update. Medical Clinics of North America, 1979, 63, 729-743.	2.5	13
5	Measles and canine distemper virus antibodies in patients with multiple sclerosis determined by radioimmunoassay. Acta Neurologica Scandinavica, 1980, 62, 81-89.	2.1	14
6	Leucocyte glutathione peroxidase activity and selenium level in multiple sclerosis. Journal of the Neurological Sciences, 1980, 48, 61-67.	0.6	45
7	Synthetic gene frequency maps of man and selective effects of climate. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 2638-2642.	7.1	96
8	A goodness-of-fit test for the polygenic threshold model: Application to multiple sclerosis. American Journal of Medical Genetics Part A, 1981, 8, 355-361.	2.4	10
9	GEOGRAPHICAL CLUES ABOUT MULTIPLE SCLEROSIS. Annals of the American Association of Geographers, 1981, 71, 28-39.	3.0	22
10	Factors Associated With a Malignant or Benign Course of Multiple Sclerosis. JAMA - Journal of the American Medical Association, 1982, 248, 856.	7.4	29
11	IgG (Gm) allotypes and multiple sclerosis in a French population: Phenotype distribution and quantitative abnormalities in CSF with respect to sex, disease severity, and presence of intrathecal antibodies. Clinical Immunology and Immunopathology, 1985, 37, 143-153.	2.0	20
12	A review of the sheep-multiple sclerosis connection. Medical Hypotheses, 1986, 19, 27-39.	1.5	30
13	The incidence and prevalence of multiple sclerosis in Newfoundland and Labrador, 1960â€“1984. Annals of Neurology, 1986, 20, 323-328.	5.3	41
14	Geotoxicology of multiple sclerosis: The Henribourg, Saskatchewan, cluster focus II. The soil. Science of the Total Environment, 1988, 77, 175-188.	8.0	36
15	Lyme borreliosis and multiple sclerosis. Biomedicine and Pharmacotherapy, 1989, 43, 415-419.	5.6	14
16	Geotoxicology of multiple sclerosis: The Henribourg, Saskatchewan, cluster focus I. The water. Science of the Total Environment, 1989, 84, 45-59.	8.0	19
17	The social epidemiology of multiple sclerosis. Science of the Total Environment, 1990, 90, 163-190.	8.0	32
18	A review of the aetiology of multiple sclerosis: an ecological approach. Annals of Human Biology, 1991, 18, 95-112.	1.0	23

#	ARTICLE	IF	CITATIONS
19	Multiple Sclerosis: The Role of Puberty and the Pineal Gland in its Pathogenesis. <i>International Journal of Neuroscience</i> , 1993, 68, 209-225.	1.6	24
20	Epidemiologic evidence for multiple sclerosis as an infection. <i>Clinical Microbiology Reviews</i> , 1993, 6, 382-427.	13.6	426
21	Epidemiology of Multiple Sclerosis: A Critical Overview. <i>Canadian Journal of Neurological Sciences</i> , 1993, 20, 17-29.	0.5	267
22	The role of genetic factors in multiple sclerosis susceptibility. <i>Journal of Neuroimmunology</i> , 1994, 54, 1-17.	2.3	178
23	Case finding for epidemiological surveys of multiple sclerosis in United States communities. <i>Multiple Sclerosis Journal</i> , 1995, 1, 48-55.	3.0	16
24	Molecular Approaches to the Identification of Unculturable Infectious Agents. <i>Emerging Infectious Diseases</i> , 1996, 2, 159-167.	4.3	57
25	Genetic epidemiology of multiple sclerosis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 553-561.	1.9	85
26	Genetic Epidemiology of Multiple Sclerosis. <i>Epidemiologic Reviews</i> , 1997, 19, 99-106.	3.5	55
27	Neurological complications to vaccination against Japanese encephalitis. <i>European Journal of Neurology</i> , 1998, 5, 479-485.	3.3	57
28	Genetics of Multiple Sclerosis. <i>Seminars in Neurology</i> , 1998, 18, 295-299.	1.4	55
29	Viruses and autoimmune disease – two sides of the same coin?. <i>Trends in Microbiology</i> , 2001, 9, 377-381.	7.7	37
30	Increasing prevalence of multiple sclerosis in Finland. <i>Acta Neurologica Scandinavica</i> , 2001, 103, 153-158.	2.1	76
31	Regional Variation in Multiple Sclerosis Prevalence in Australia and Its Association with Ambient Ultraviolet Radiation. <i>Neuroepidemiology</i> , 2001, 20, 168-174.	2.3	195
32	Principles of clinical neuro-epidemiology. , 2002, , 118-126.		0
33	Frontal fluency and memory functioning among multiple sclerosis patients in Hong Kong. <i>Brain Injury</i> , 2002, 16, 987-995.	1.2	13
34	The prevalence and clinical characteristics of MS in northern Japan. <i>Journal of the Neurological Sciences</i> , 2003, 211, 49-53.	0.6	48
35	Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 25-28.	1.9	48
36	Challenges in Addressing Community Concerns Regarding Clusters of Multiple Sclerosis and Potential Environmental Exposures. <i>Neuroepidemiology</i> , 2004, 23, 211-216.	2.3	9

#	ARTICLE	IF	CITATIONS
37	Health effects of dental amalgam exposure: a retrospective cohort study. <i>International Journal of Epidemiology</i> , 2004, 33, 894-902.	1.9	82
38	A cluster of multiple sclerosis cases in Lysvik in the Swedish county of Varmland. <i>Acta Neurologica Scandinavica</i> , 2004, 110, 14-22.	2.1	9
39	Occurrence of multiple sclerosis in central Finland: a regional and temporal comparison during 30 years. <i>Acta Neurologica Scandinavica</i> , 2004, 110, 331-336.	2.1	54
40	Vitamin D intake and incidence of multiple sclerosis. <i>Neurology</i> , 2004, 62, 60-65.	1.1	930
41	Mortality of Multiple Sclerosis in Spain: Demonstration of a North-South Gradient. <i>Neuroepidemiology</i> , 2005, 24, 135-140.	2.3	12
42	A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1294-1296.	1.9	160
43	25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 266-271.	3.0	211
44	Role of health-related quality of life measures in the routine care of people with multiple sclerosis. <i>Health and Quality of Life Outcomes</i> , 2005, 3, 16.	2.4	67
45	Suggesting the possible role of Turkey Herpesvirus or HVT-like as a predisposing factor or causative agent in multiple sclerosis. <i>Medical Hypotheses</i> , 2006, 67, 926-929.	1.5	2
47	Vitamin D as a Neuroactive Substance: Review. <i>Scientific World Journal, The</i> , 2006, 6, 125-139.	2.1	90
48	A new era in the genetic analysis of multiple sclerosis. <i>Current Opinion in Neurology</i> , 2006, 19, 237-241.	3.6	17
49	Differential twin concordance for multiple sclerosis by latitude of birthplace. <i>Annals of Neurology</i> , 2006, 60, 56-64.	5.3	96
50	Vitamin D: Status, Supplementation and Immunomodulation. <i>Current Nutrition and Food Science</i> , 2006, 2, 315-336.	0.6	1
51	Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. <i>Multiple Sclerosis Journal</i> , 2007, 13, 670-672.	3.0	53
52	Vitamin D and Parkinson's disease—A hypothesis. <i>Movement Disorders</i> , 2007, 22, 461-468.	3.9	154
53	Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. <i>Internal Medicine Journal</i> , 2008, 38, 816-823.	0.8	85
54	A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 152-157.	1.9	186
55	The noncalcitropic actions of vitamin D: recent clinical developments. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 408-415.	2.0	52

#	ARTICLE	IF	CITATIONS
56	Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. <i>American Journal of Clinical Nutrition</i> , 2008, 88, 441-447.	4.7	223
57	Epidemiological investigations into multiple sclerosis in Southern Hesse I.. <i>Acta Neurologica Scandinavica</i> , 1984, 70, 257-265.	2.1	25
58	Epidemiology of multiple sclerosis in Western Poland - a comparison between prevalence rates in 1965 and 1981. <i>Acta Neurologica Scandinavica</i> , 1985, 72, 210-217.	2.1	20
59	Reflection on the geographic distribution of multiple sclerosis in France. <i>Acta Neurologica Scandinavica</i> , 1996, 93, 110-117.	2.1	21
60	Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. <i>Multiple Sclerosis Journal</i> , 2009, 15, 9-15.	3.0	177
61	New hypotheses on sunlight and the geographic variability of multiple sclerosis prevalence. <i>Journal of the Neurological Sciences</i> , 2010, 292, 5-10.	0.6	36
62	Vitamin D and multiple sclerosis: can vitamin D prevent disease progression?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 469-471.	2.8	5
63	Individual and Joint Action of Environmental Factors and Risk of MS. <i>Neurologic Clinics</i> , 2011, 29, 233-255.	1.8	63
64	Role of vitamin D in multiple sclerosis: implications for disease management. <i>Neurodegenerative Disease Management</i> , 2011, 1, 523-536.	2.2	4
65	Third time's a charm: Causation, science and Wittgensteinian pluralism. , 2011, , 907-928.		9
66	Effect of High-Dose Vitamin D3 Intake on Ambulation, Muscular Pain and Bone Mineral Density in a Woman with Multiple Sclerosis: A 10-Year Longitudinal Case Report. <i>International Journal of Molecular Sciences</i> , 2012, 13, 13461-13483.	4.1	8
67	Vitamin D and Multiple Sclerosis. <i>Neurologist</i> , 2012, 18, 179-183.	0.7	20
68	Autonomic dysfunction: A unifying multiple sclerosis theory, linking chronic cerebrospinal venous insufficiency, vitamin D3, and Epstein-Barr virus. <i>Autoimmunity Reviews</i> , 2012, 12, 250-259.	5.8	27
69	Rising incidence of multiple sclerosis in females associated with urbanization. <i>Neurology</i> , 2012, 78, 1728-1735.	1.1	98
70	Serum Vitamin D Levels in Indian Patients with Multiple Sclerosis. <i>Indian Journal of Clinical Biochemistry</i> , 2013, 28, 255-258.	1.9	4
71	Melatonin: Buffering the Immune System. <i>International Journal of Molecular Sciences</i> , 2013, 14, 8638-8683.	4.1	532
72	Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis. <i>Proteomics - Clinical Applications</i> , 2013, 7, 91-108.	1.6	13
73	Frequency of reported European ancestry among multiple sclerosis patients from four cities in the southern and southeastern regions of Brazil. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1642-1646.	1.4	5

#	ARTICLE	IF	CITATIONS
74	A proposed methodology to estimate the cumulative life-time UVB exposure using geographic information systems: An application to multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 29-35.	2.0	6
75	European Ancestry Predominates in Neuromyelitis Optica and Multiple Sclerosis Patients from Brazil. <i>PLoS ONE</i> , 2013, 8, e58925.	2.5	14
76	Multiple Facets of Melatonin in Immunity: Clinical Applications. , 2014, , 117-141.		1
78	Early prognosis of multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 371-391.	1.8	15
79	Vitamin D Therapy in Experimental Allergic Encephalomyelitis Could be Limited by Opposing Effects of Sphingosine 1-Phosphate and Gelsolin Dysregulation. <i>Molecular Neurobiology</i> , 2014, 50, 733-743.	4.0	10
80	Disease modification in multiple sclerosis: an update. <i>Practical Neurology</i> , 2014, 14, 6-13.	1.1	12
81	Long-term epidemiology of multiple sclerosis in the northern Swedish district. <i>Acta Neurologica Scandinavica</i> , 2015, 132, 111-117.	2.1	32
82	Immunogenetics of Neurological Disease. , 2015, , 39-50.		0
83	The role of epidemiology in MS research: Past successes, current challenges and future potential. <i>Multiple Sclerosis Journal</i> , 2015, 21, 969-977.	3.0	37
84	Presence of the HLADR13 allele among Mexican Mestizos suggests a protective factor against relapsing-remitting multiple sclerosis (RRMS). <i>Clinical Neurology and Neurosurgery</i> , 2015, 138, 184-187.	1.4	3
85	John F Kurtzke. <i>BMJ</i> , The, 2016, , i584.	6.0	0
86	Multiple Sclerosis. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 195-204.	1.0	51
87	The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 30-34.	2.0	8
88	Epigenetics in Multiple Sclerosis: Molecular Mechanisms and Dietary Intervention. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2018, 18, 8-15.	1.1	9
89	Hypothesis: Multiple sclerosis is caused by three-hits, strictly in order, in genetically susceptible persons. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 157-174.	2.0	12
90	Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland 2010–2017: findings from the Scottish Multiple Sclerosis Register. <i>Journal of Neurology</i> , 2019, 266, 2376-2386.	3.6	22
91	Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)2D, but No Difference in Ratio of 25(OH)D/24,25(OH)2D and FGF23 Concentrations. <i>Nutrients</i> , 2019, 11, 2774.	4.1	10
93	EBNA1, EBNA2, and EBNA3 link Epstein-Barr virus and hypovitaminosis D in multiple sclerosis pathogenesis. <i>Journal of Neuroimmunology</i> , 2020, 339, 577116.	2.3	14

#	ARTICLE	IF	CITATIONS
94	Association of Multiple Sclerosis with PM 2.5 levels. Further evidence from the highly polluted area of Padua Province, Italy. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102677.	2.0	8
95	The latitude gradient for multiple sclerosis prevalence is established in the early life course. <i>Brain</i> , 2021, 144, 2038-2046.	7.6	25
97	Temporal trends in the incidence and prevalence of Multiple Sclerosis in the Northwest of Spain. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102979.	2.0	2
98	Benign Multiple Sclerosis: A Distinct Clinical Entity with Therapeutic Implications. <i>Current Topics in Microbiology and Immunology</i> , 2008, 318, 1-17.	1.1	19
99	<i>Neuropathologie.</i> , 1984, , 1-287.		2
100	Evolution in Human Populations: Data and Models. <i>Lecture Notes in Biomathematics</i> , 1980, , 98-132.	0.3	2
101	Driver health and traffic safety: an overview. , 2009, , 1-22.		3
102	Immunogenetics of multiple sclerosis. , 1984, , 177-206.		9
103	Molecular Mimicry and Central Nervous System Autoimmune Disease. , 0, , 27-38.		3
104	The role of melatonin in autoimmune and atopic diseases. <i>AIMS Molecular Science</i> , 2016, 3, 158-186.	0.5	5
105	Gene therapy for multiple sclerosis. , 2000, , 119-131.		0
107	Urban/Rural Differences in Hospital Admissions with Multiple Sclerosis in Selected Counties in Ohio 1999-2004. <i>The Open Epidemiology Journal</i> , 2009, 2, 51-54.	1.0	1
109	Vitamin d3 concentration correlates with the severity of multiple sclerosis. <i>International Journal of Preventive Medicine</i> , 2013, 4, 585-91.	0.4	16
110	Association of serum 25(OH) vitamin D3 concentration with severity of multiple sclerosis. <i>Iranian Journal of Neurology</i> , 2012, 11, 54-8.	0.5	16
111	Mechanisms of pathophysiology of blood vessels in patients with multiple sclerosis treated with ozone therapy: a systematic review. <i>Acta Biomedica</i> , 2019, 90, 213-217.	0.3	8
112	Sex differences in vitamin D metabolism, serum levels and action. <i>British Journal of Nutrition</i> , 2022, 128, 2115-2130.	2.3	28
113	Metabolomics as a promising tool for improving understanding of multiple sclerosis: A review of recent advances. <i>Biomedical Journal</i> , 2022, 45, 594-606.	3.1	13
116	Therapeutic Role of Vitamin D in Multiple Sclerosis: An Essentially Contested Concept. <i>Cureus</i> , 2022, , .	0.5	6

#	ARTICLE	IF	CITATIONS
117	Melatonin and Health: Insights of Melatonin Action, Biological Functions, and Associated Disorders. Cellular and Molecular Neurobiology, 2023, 43, 2437-2458.	3.3	27
119	Making Sure Multiple Sclerosis Counts and Is Counted for All – An Update on Multiple Sclerosis Prevalence by Race and Ethnicity in the United States. JAMA Neurology, 2023, 80, 667.	9.0	0
120	Seven Strategies to Integrate Equity within Translational Research in Neurology. Annals of Neurology, 2024, 95, 432-441.	5.3	0